UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.248

Sortiert nach

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis

The Lancet (British edition), 2010-10, Vol.376 (9749), p.1312-1319

2010

Volltextzugriff (PDF)

Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial

The Lancet (British edition), 2015-06, Vol.385 (9984), p.2280-2287

2015

Volltextzugriff (PDF)

Cytochrome P-450 Polymorphisms and Response to Clopidogrel

The New England journal of medicine, 2009-01, Vol.360 (4), p.354-362

2009

Volltextzugriff (PDF)

Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes

Circulation (New York, N.Y.), 2009-05, Vol.119 (19), p.2553-2560

2009

Volltextzugriff (PDF)

The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease

Thrombosis and haemostasis, 2014, Vol.112 (3), p.589

2014

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants

British journal of clinical pharmacology, 2012-01, Vol.73 (1), p.93-105

2012

Volltextzugriff (PDF)

Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease

Thrombosis and haemostasis, 2014, Vol.111 (5), p.943

2014

Volltextzugriff (PDF)

PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes

Journal of thrombosis and thrombolysis, 2016-04, Vol.41 (3), p.374-383

2016

Volltextzugriff (PDF)

Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension

Clinical pharmacology and therapeutics, 2004-12, Vol.76 (6), p.536-544

2004

Volltextzugriff (PDF)

Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways

Thrombosis and haemostasis, 2013-12, Vol.110 (6), p.1223

2013

Volltextzugriff (PDF)

β-adrenergic Receptor Polymorphisms and Responses during Titration of Metoprolol Controlled Release/extended Release in Heart Failure

Clinical pharmacology and therapeutics, 2005-03, Vol.77 (3), p.127-137

2005

Volltextzugriff (PDF)

Population Exposure-Response Modeling of Metformin in Patients With Type 2 Diabetes Mellitus

Journal of clinical pharmacology, 2008-06, Vol.48 (6), p.696-707

2008

Volltextzugriff (PDF)

Population Pharmacokinetic Model for a Novel Oral Hypoglycemic Formed In Vivo: Comparing the Use of Active Metabolite Data Alone Versus Using Data of Upstream and Downstream Metabolites

Journal of clinical pharmacology, 2012-03, Vol.52 (3), p.404-415

2012

Volltextzugriff (PDF)

Effect of the Bile Acid Sequestrant Colesevelam on the Pharmacokinetics of Pioglitazone, Repaglinide, Estrogen Estradiol, Norethindrone, Levothyroxine, and Glyburide

Journal of clinical pharmacology, 2010-05, Vol.50 (5), p.554-565

2010

Volltextzugriff (PDF)

Quantitative Structure-Property Relationships Modeling to Predict In Vitro and In Vivo Binding of Drugs to the Bile Sequestrant, Colesevelam (Welchol)

Journal of clinical pharmacology, 2009-10, Vol.49 (10), p.1185-1195

2009

Volltextzugriff (PDF)

ABCB1 GENETIC VARIANTS, PHARMACODYNAMIC RESPONSE, AND CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH CLOPIDOGREL AND PRASUGREL

Journal of the American College of Cardiology, 2010-03, Vol.55 (10), p.A113.E1056-A113.E1056

2010

Volltextzugriff (PDF)

Abstract 9871: Enhanced Active Metabolite Generation and Platelet Inhibition With Prasugrel Compared to Clopidogrel Regardless of Genotype in Thienopyridine Metabolic Pathways

Circulation (New York, N.Y.), 2012-11, Vol.126 (suppl_21)

2012

Volltextzugriff (PDF)

Genetic Variants in ABCB1, CYP2C19, and Cardiovascular Outcomes Following Treatment with Clopidogrel and Prasugrel

The Lancet (British edition), 2010-10, Vol.376 (9749), p.1312-1319

2010

Volltextzugriff (PDF)

Abstract 1439: Cytochrome P450 Genetic Variants Predict Cardiovascular Outcomes following Treatment with Clopidogrel but not with Prasugrel

Circulation (New York, N.Y.), 2008-10, Vol.118 (suppl_18)

2008

Volltextzugriff (PDF)

β-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Commentary

Clinical pharmacology and therapeutics, 2005, Vol.77 (3), p.123-126

2005

Volltextzugriff (PDF)

Inheritance of White Plumage in Pigeons

Genetics (Austin), 1925-11, Vol.10 (6), p.593-604

Walker, J R

1925

Volltextzugriff (PDF)

Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease?

Trends in neurosciences (Regular ed.), 2016-08, Vol.39 (8), p.552-566

2016

Volltextzugriff (PDF)

Sleep and Human Aging

Neuron (Cambridge, Mass.), 2017-04, Vol.94 (1), p.19-36

2017

Volltextzugriff (PDF)

Prime editing in mice reveals the essentiality of a single base in driving tissue-specific gene expression

Genome Biology, 2021-03, Vol.22 (1), p.83-83, Article 83

2021

Volltextzugriff (PDF)

The Oslo definitions for coeliac disease and related terms

Gut, 2013-01, Vol.62 (1), p.43-52

2013

Volltextzugriff (PDF)

1 – 25 von 1.248

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.131)
Mit Volltextzugriff
(1.080)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.242)
Japanisch
(161)
Norwegisch
(2)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis

Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial

Cytochrome P-450 Polymorphisms and Response to Clopidogrel

Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes

The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease

Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants

Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease

PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes

Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension

Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways

β-adrenergic Receptor Polymorphisms and Responses during Titration of Metoprolol Controlled Release/extended Release in Heart Failure

Population Exposure-Response Modeling of Metformin in Patients With Type 2 Diabetes Mellitus

Population Pharmacokinetic Model for a Novel Oral Hypoglycemic Formed In Vivo: Comparing the Use of Active Metabolite Data Alone Versus Using Data of Upstream and Downstream Metabolites

Effect of the Bile Acid Sequestrant Colesevelam on the Pharmacokinetics of Pioglitazone, Repaglinide, Estrogen Estradiol, Norethindrone, Levothyroxine, and Glyburide

Quantitative Structure-Property Relationships Modeling to Predict In Vitro and In Vivo Binding of Drugs to the Bile Sequestrant, Colesevelam (Welchol)

ABCB1 GENETIC VARIANTS, PHARMACODYNAMIC RESPONSE, AND CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH CLOPIDOGREL AND PRASUGREL

Abstract 9871: Enhanced Active Metabolite Generation and Platelet Inhibition With Prasugrel Compared to Clopidogrel Regardless of Genotype in Thienopyridine Metabolic Pathways

Genetic Variants in ABCB1, CYP2C19, and Cardiovascular Outcomes Following Treatment with Clopidogrel and Prasugrel

Abstract 1439: Cytochrome P450 Genetic Variants Predict Cardiovascular Outcomes following Treatment with Clopidogrel but not with Prasugrel

β-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Commentary

Inheritance of White Plumage in Pigeons

Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease?

Sleep and Human Aging

Prime editing in mice reveals the essentiality of a single base in driving tissue-specific gene expression

The Oslo definitions for coeliac disease and related terms

Suchergebnisse filtern